Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
Condition(s):UC (Urothelial Cancer)Last Updated:December 16, 2021Completed
Hide Studies Not Open or Pending
Condition(s):UC (Urothelial Cancer)Last Updated:December 16, 2021Completed
Condition(s):UC (Urothelial Cancer)Last Updated:November 30, 2021Completed
Condition(s):Metastatic Colorectal CancerLast Updated:August 28, 2018Withdrawn
Condition(s):Rectal CancerLast Updated:July 25, 2023Recruiting
Condition(s):Lung CancerLast Updated:January 24, 2022Completed
Condition(s):Gastrointestinal Stromal TumorsLast Updated:March 19, 2021Completed
Condition(s):Solid TumorsLast Updated:May 21, 2020Terminated
Condition(s):Thymic Carcinoma; Thymus Neoplasms; Thymus CancerLast Updated:December 13, 2019Unknown status
Condition(s):Advanced Solid Tumor; Non-small Cell Lung Cancer (NSCLC)Last Updated:May 3, 2023Active, not recruiting
Condition(s):Lung CancerLast Updated:January 24, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.